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Background
NAMPT (Nicotinamide phosphoribosyltransferase) cata-
lyzes the rate-limiting step in the NAD-biosynthesis
from nicotinamide and regulates the activity of NAD-
dependent enzymes. Cancer cells are highly dependent
on NAD for energy and DNA repair processes and are
expected to be more susceptible to the inhibition of
NAD synthesis than non-transformed cells. Can inhibi-
tion of NAMPT by FK866 sensitize leukemia cells for
chemotherapeutic agents?
Materials and methods
Viability was measured using WST-1 assay. Cell death was
analysed in Jurkat and Molt-4 cells by PI staining. NAD
levels were measured using a colorimetric NAD/NADH
Assay or HPLC. NAMPT activity was measured in leuke-
mia cell lines and PBMCs (peripheral blood mononuclear
cell) using radioactively labelled 14C-nicotinamide.
Results
NAMPT expression and enzymatic activity were signifi-
cantly higher in leukemia cell lines compared to normal
PBMCs. Incubation with FK866 [10nM] for 24h reduced
NAMPT activity by 91.1±3.6% in Jurkat cells and by 97.8
±1.2% in Molt-4 cells. NAD levels were reduced by
FK866 by 83.9±1.0% (Jurkat) or 79.2±2.8% (Molt-4). The
combination of etoposide and FK866 caused increased
cell death compared to each substance alone. In contrast,
combining FK866 and methotrexate or doxorubicin
showed no increased effect on cell death. Etoposide
decreased the expression of the NAD-dependent deacety-
lase SIRTUIN1 (SIRT1). The acetylation of the SIRT1
target p53 was increased after stimulation with etoposide
and was further enhanced after combining etoposide
with FK866. Concomitantly, the transcriptional activity
of p53 was increased as shown by an increased expres-
sion of p21.
Conclusion
The combination of etoposide and FK866 caused increased
cell death and induced acetylation and transcriptional
activity of p53. Combining FK866 and etoposide could
therefore be a novel therapeutic strategy to enhance the
efficacy of etoposide against leukemia cells.
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